Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECISIONS Trial: N-acetylcysteine in IPF Patients with TOLLIP TT Genotype
NCT04300920Phase 3Completed
- Start
- Dec 2020
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing N-acetylcysteine with Placebo (2 arms). Primary endpoint: Time to composite endpoint (10% relative decline in FVC, first respiratory hospitalization, lung transplant or death from any cause) at 24 months. Started Dec 2020; status: completed.
02
Drugs
acetylcysteine
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04300920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04300920.